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Oral anticoagulation for cardiothoracic patients has
traditionally been synonymous with the use of warfarin.
The recent introduction of new oral anticoagulants
(NOACs) targeting factor Xa or thrombin represents a
new approach for anticoagulation. Cardiothoracic surgeons
need to familiarize themselves with these agents, because
more preoperative patients will be taking NOACs. Thus,
strategies for discontinuation before surgery with or without
bridging have become paramount. The rapid onset of
action, wide therapeutic index, and a steady therapeutic
state without the need for monitoring has made these new
agents more attractive than warfarin for these indications.
The currently available NOACs are dabigatran etexilate
(Pradaxa; Boehringer Ingelheim, Ridgefield, Conn),
rivaroxaban (Xarelto; Bayer HealthCare AG, Leverkusen,
Germany), apixaban (Eliquis; Bristol-Myers Squibb,
New York, NY), and edoxaban (Savaysa; Daiichi Sankyo,
Tokyo, Japan; not approved in the United States). We
have reviewed the pharmacologic profile, clinical evidence
for safety and efficacy, currently approved indications, and
strategies to guide in the perioperative treatment of patients
taking NOACs.
TRADITIONAL ORAL ANTICOAGULANT—
WARFARIN
Warfarinwas approved for humanuse in 1954andhas been
themainstay oral anticoagulant in clinical practice ever since,
until recently.Warfarin inhibits vitaminK-dependant synthe-
sis of calcium-dependant clotting factors and the regulatory
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the use of warfarin (Table 1 and Appendix 1). The narrow
therapeutic indexwith frequentmonitoring has been a burden
of therapy because of the frequent dose adjustment needed,
and the long half-life of warfarin (approximately 60 hours)
requires several days to restore the therapeutic anticoagula-
tion level after interruption.
One major advantage compared with NOACs is its
reversibility. In an emergency setting, warfarin can be
reversed with fresh frozen plasma, and patients can undergo
a procedure safely. Vitamin K provides excess cofactor for
ongoing coagulation factor carboxylation in the setting of
irreversible inhibition by warfarin and, therefore, requires
synthesis of new coagulation factors to have an effect. For
additional information on warfarin, see Appendix 1.
These limitations have led to development of NOACs
targeting factor Xa or thrombin (factor IIa).
USE OF WARFARIN IN CARDIOTHORACIC
SURGERY
We reviewed the use of warfarin after cardiac surgery at
Brigham andWomen’sHospital. In 2011, of 1257 cardiac cases
performed, 586 patients (46.6%) were discharged with
warfarin. Similarly, in 2012, of 1234 cardiac cases performed,
557 patients (45.1%) were discharged with warfarin. These
data included all patients who were taking warfarin; hence,
both patients who were taking it preoperatively and had started
taking it postoperatively were counted.
PHARMACOKINETIC AND PHARMACODYNAMIC
PROFILE OF ORAL ANTICOAGULANTS
The characteristics of dabigatran, rivaroxaban, apixaban,
and edoxaban are compared with warfarin in Table 1.
Dabigatran
Dabigatran etexilate is a direct thrombin inhibitor and
comes in the form of a prodrug with a bioavailability of
7.2%.1 It is converted to the active form dabigatran in
the liver. It directly blocks the active site and prevents
conversion of fibrinogen into fibrin. The half-life of
dabigatran is about 13 hours in healthy individuals and is
cleared by the kidneys (renal excretion, 80%). Renal
function should be monitored in patients with renal
insufficiency, because poor renal function can impair
renal excretion and prolong the effect of anticoagulation.
Accordingly, the dose adjustment should be determined
by the creatinine clearance (Table 1). Interaction withgery c November 2014
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Kaneko et al Expert Reviewpermeability glycoprotein (p-gp) inhibitors such as
quinidine, ketoconazole, and verapamil can increase the
plasma concentration by reducing the clearance of
dabigatran etexilate.2 This is more significant in patients
with renal failure, and patients with severe renal impairment
(creatinine clearance<30 mL/min) should not be taking a
p-gp inhibitor and dabigatran. Because the plasma
concentration and anticoagulant effect are dose dependent
and predictable, it does not require repeated monitoring,
unlike warfarin. The peak effect occurs within 0.5 to
2 hours, with a steady state achieved within 3 days.3
It is known that a plasma trough dabigatran level of
<50 ng/mL is associated with an increased risk of
thromboembolism4; however, the trough level is not
commonly measured clinically at this point.
Rivaroxaban
Rivaroxaban, which is derived from 2-oxazolidone, is an
oral inhibitor of factor Xa, binding reversibly to its active
site. Rivaroxaban has an oral bioavailability of 80%, and
a half-life of 7 to 11 hours; 67% is cleared renally but
approximately one half of that is excreted unchanged in
the urine.5 In addition to interaction with p-gp inhibitors,
rivaroxaban is metabolized by way of CYP3A4; thus, strong
inhibitors of CYP3A4, such as human immunodeficiencyThe Journal of Thoracic and Carvirus protease inhibitors, macrolide antibiotics (erythro-
mycin), and azole antifungal agents (eg, ketoconazole),
should be avoided because these agents will increase the
risk of bleeding. No monitoring is required for rivaroxaban.
It is the only NOAC approved by the Food and Drug
Administration (FDA) approved for once daily dose.
Apixaban
Apixaban is an oral direct inhibitor of factor Xa, and its
bioavailability is 66%. Its half-life is approximately 12.7
hours, and 25% of the drug is cleared renally.6 Administration
of a strong dual inhibitor of CYP3A4 plus a p-gp (ie, ketocona-
zole, itraconazole, ritonavir, or clarithromycin) will increase the
risk of bleeding and should be avoided.
Edoxaban
Edoxaban is also an oral direct inhibitor of factor Xa. Its
bioavailability is 62%, and the half-life is 10 to 14 hours,
which allows daily dosing. Approximately 50% of drug is
renally excreted. Because Edoxaban is p-gp transporter, it
has interactions with strong p-gp inhibitors but minimal
interaction with CYP3A4 inhibitors.7
Interactions With Amiodarone and Dronedarone
It is worth emphasizing that because amiodarone is a
moderate p-gp inhibitor and dronedarone a strong p-gp
inhibitor, using dabigatran, rivaroxaban, and apixaban
for patients with either amiodarone or dronedarone can
increase the effect of anticoagulation about 50% and,
therefore, should be avoided.2 This effect is smaller
with edoxaban, and amiodarone and edoxaban can be
administered if one of the doses is decreased. In contrast,
dronedarone is a strong p-gp inhibitor, and the dose of
edoxaban should be reduced by 50% if dronedarone is
co-administered.7 Safe concomitant use of amiodarone
and apixaban have been reported.8
The currently approved indications and dosage for
NOACs are listed in Table 1 and Appendix 1. Advantages
and disadvantages of NOACs compared with warfarin are
listed in Table 2.
CLINICAL EVIDENCE FOR NOACs
Prevention of Stroke in Patients With Atrial
Fibrillation
Dabigatran, rivaroxaban, and apixaban have been
approved by the FDA for prevention of stroke in patients
with nonvalvular atrial fibrillation (AF) on the basis of the
following results.
The Randomized Evaluation of Long-Term Anticoagula-
tion Therapy (RE-LY) trial compared 2 doses of dabigatran
(110 mg twice daily or 150 mg twice daily) with warfarin
(international normalized ratio [INR], 2-3) for stroke pre-
vention in patients with nonvalvular AF and 1 risk factor
for stroke.9 For the prevention of the composite outcome ofdiovascular Surgery c Volume 148, Number 5 1795
TABLE 1. Characteristics of new anticoagulants compared with warfarin
Variable Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of
action
Vitamin K antagonist Thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor
T1/2 (h) 40 13 7-11 12.7 10-14
Excretion Renal (metabolized in
liver)
Renal (80%) Renal (66%)/
hepatobiliary
Renal (25%)/fecal Renal (50%)/fecal
Bioavailability (%) 95 7.2 80 66 62
Drug interactions Multiple (see Appendix 1) Inhibitors of p-gp Inhibitors of p-gp
and CYP3A4
Inhibitors of p-gp
and CYP3A4
Inhibitors of p-gp
Food interactions Leafy green vegetables
(high in vitamin K),
alcohol, cranberry juice
No No No No
Monitoring Yes No No No No
Approved dose Variable 150 mg bid (AF);
110 mg bid
(AF-Europe)
10 mg daily (VTE)
20 mg daily (AF)
15 mg bid for first 21 d,
then 20 mg daily
(treatment of DVT)
5 mg bid (AF) 30 mg daily (VTE,
Japan) 60 mg daily
for VTE, 30 or 60 mg
daily for AF (FDA
and Europe pending
approval)
Dose reduction Depending on INR 75 mg bid for CrCl
30-50 mL/min
Consider stopping
for acute renal
failure (AF)
Avoid use with
p-gp inhibitor,
rifampin
15 mg daily for CrCl
15-50 mL/min (AF)
Avoid use in strong
dual inhibitor of
p-gp and CYP3A4
2.5 mg bid (AF) for 2
of the following: age
>80 y, body weight
<60 kg, Cr>1.5 mg/dL
2.5 mg bid or stop when
used with strong dual
inhibitor of p-gp and
CYP3A4
Reduce to half dose for
CrCl 30-50 mL/min,
weight 60 kg, or
were taking a potent
p-gp inhibitor
Approved
indications (FDA)
Prevention and treatment
of VTE, AF,
mechanical valves
Nonvalvular AF,
treatment of DVT,
prevention of VTE
recurrence
VTE prevention after hip
or knee replacement,
nonvalvular AF,
treatment of DVT,
prevention of VTE
recurrence
Nonvalvular AF, VTE
prevention after hip
or knee replacement
Not approved
T1/2, Half-life; p-gp, permeability glycoprotein; bid, twice daily; AF, atrial fibrillation; VTE, venous thromboembolism;DVT, deep venous thromboembolism; FDA, US Food and
Drug Administration; INR, international normalized ratio; CrCl, creatinine clearance; Cr, creatinine.
Expert Review Kaneko et alstroke or systemic embolism, dabigatran 110mg twice daily
was not inferior to warfarin, and dabigatran 150 mg twice
daily was superior to warfarin. The incidence of intracra-
nial, life-threatening, or any type of bleeding was reduced
in both dabigatran dosage groups, and low-dose dabigatran
also reduced the incidence of major bleeding. The
high-dose dabigatran group had a greater incidence of
gastrointestinal bleeding. The original report had a signifi-
cantly greater incidence statistically of myocardial infarc-
tion in the 150-mg dabigatran group compared with the
warfarin group; however, after readjudication of myocardial
infarction, the difference was nonsignificant.10 The FDA
did not approve the 110-mg twice daily dose, however, cit-
ing that they could not identify a subgroup of patients for
whom the lower dose would be preferred over the higher
dose.11
The Rivaroxaban Once-daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial1796 The Journal of Thoracic and Cardiovascular SurFibrillation (ROCKET AF) compared rivaroxaban 20 mg
daily with warfarin (INR, 2-3).12 For the primary endpoint
of stroke and systemic embolism, rivaroxaban was not
inferior to warfarin. The rates of major and nonmajor
clinically relevant bleeding events were similar, and
significant reductions in the rate of intracranial hemorrhage
and fatal bleeding occurred in the rivaroxaban group.
However, an increase in major gastrointestinal bleeding
was observed in the rivaroxaban group.
The Apixaban for Reduction in Stroke and Other Throm-
boembolic Events in Atrial Fibrillation (ARISTOTLE) trial
compared apixaban 5 mg twice daily with warfarin (INR,
2-3).13 Apixaban was superior to warfarin for the primary
endpoint of the composite outcome of stroke and systemic
embolism. The rate of major bleeding events, intracranial
hemorrhage, and all-cause mortality were all significantly
lower in the apixaban group. No difference was seen in
the incidence of gastrointestinal bleeding between the 2
groups.gery c November 2014
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Generation in Atrial Fibrillation—Thrombolysis in
Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial
was recently published. That trial compared 30 mg
and 60 mg once daily edoxaban to warfarin.14 Edoxa-
ban in both dosages was not inferior to warfarin
when compared using the primary endpoint of stroke
or systemic embolism. The annualized rates of major
bleeding and causes of cardiovascular death were signif-
icantly lower in both edoxaban groups compared with
warfarin. Major gastrointestinal bleeding was less
frequent with low-dose edoxaban than with warfarin
but was more frequent with high-dose edoxaban than
with warfarin.
A recent meta-analysis of all 4 randomized warfarin-
controlled studies showed that NOACs significantly
reduced stroke or systemic embolic events by 19%
compared with warfarin, mainly by reducing hemorrhagic
stroke.15 NOACs also reduced all-cause mortality and
intracranial hemorrhage but resulted in an increased
incidence of gastrointestinal bleeding. See Appendix 1 for
the incidence of gastrointestinal bleeding with the use of
NOACs. Adverse events of NOACs in major atrial fibrilla-
tion trial are summarized in Table 3.
Anticoagulation for Mechanical Heart Valves
An interest has developed to use NOACs for anti-
coagulation in those with prosthetic heart valves.
Dabigatran is the only drug that has been studied in this
patient population to date.
A large phase II randomized controlled study, namely the
randomized, phase II study to evaluate the safety and
pharmacokinetics of oral dabigatran etexilate in patients
after heart valve replacement (RE-ALIGN) trial, was
initiated in 2012.16 That trial included patients who had
undergone implantation of a mechanical valve (aortic or
mitral) or implantation of a mitral bileaflet valve<3 months
before randomization. The trial was terminated prematurely
owing to an increase in stroke (5% vs 0%), myocardial
infarction, and major bleeding (4% vs 2%) in the
dabigatran group compared with the warfarin group.
Thus, the FDA announced in December 2012 that
dabigatran is contraindicated for patients with mechanical
heart valves.
Several criticisms pertain to that trial. One is that nearly
80% of patients in that trial had undergone recent surgery
before the initiation of dabigatran. Early thrombogenicity
after surgery is well known, and this could have affected
the anticoagulation level. Another is the trough target of
50 ng, which was calculated from RE-LY trial. The mean
age for RE-LY trial was 71 years compared with 56 years
in the RE-ALIGN study and caused a lower than
projected plasma level of dabigatran in the first 4 weeks.
A future trial with a higher trough target and an initialThe Journal of Thoracic and Carperiod of dose adjustment might be needed to assess the
true validity.
Currently, dabigatran is contraindicated and should
not be used for patients with mechanical valves. For
bioprosthetic valves, the FDA made the following state-
ment: ‘‘The use of dabigatran in patients with bioprosthetic
valves has not been evaluated and cannot be recommen-
ded.’’ No large study of rivaroxaban, apixaban, and
edoxaban for patients with a prosthetic valve has been
performed, and their use in heart prosthesis is not
recommended. For other FDA-approved indications, see
Appendix 1 for the clinical evidence.
NONVALVULAR AF
NOACs are only approved for patients with AF that is
‘‘nonvalvular’’ in origin; however, nonvalvular AF has not
been consistently defined among the trials. Thus, questions
remain, including whether moderate mitral regurgitation
with AF denotes nonvalvular AF; and whether AF in the
presence of a bioprosthetic valve should be considered
nonvalvular AF. In the randomized controlled trials that
assessed the validity of NOACs for stroke prevention in
patients with AF, the exclusion criteria were as follows:
hemodynamically relevant valvular disease and a prosthetic
valve in the RE-LY trial,9 hemodynamically significant
mitral stenosis and a prosthetic valve in the ROCKET-AF
trial,12 moderate or severe mitral stenosis and a prosthetic
valve in the ARISTOTLE trial,13 and moderate to severe
mitral stenosis in the ENGAGE AF-TIMI 48 trial.14 Thus,
the definitions were most restrictive in the RE-LY trial
and most permissive in the ENGAGE AF-TIMI 48 trial. It
is also important to add that previous mitral valve
repair and annular rings were not exclusion criteria in these
trials. Recently published American College of Cardiology/
American Heart Association guidelines for the management
of AF have defined nonvalvular AF as that not associated
with a mechanical or bioprosthetic valve or mitral
stenosis.17
PERIOPERATIVE ISSUES
Stopping NOACs Before Surgery
Recommendations on the timing of discontinuation of
NOACs before surgery have been published.18,19 The
timing of discontinuation depends on 3 factors: the
half-life of the drug, the patient’s renal function, and the
type of surgery. Figure 1 shows the suggested management
of preoperative discontinuation of NOAC.20 Cardiotho-
racic surgery is considered major surgery; hence, more
complete reversal is required preoperatively. The last
dose should be given 4 to 5 half-lives of the drug between
the last dose and surgery, which corresponds to the mini-
mal amount of residual anticoagulation effect (3%-6%).
The latter will differ according to the patient’s renal func-
tion. In patients undergoing major surgery (eg, cardiac,diovascular Surgery c Volume 148, Number 5 1797
FIGURE 1. Perioperative management of a patient undergoing major cardiothoracic surgery who is taking (A) warfarin or (B) new oral anticoagulants
(NOACs).UFH, Unfractionated heparin; LMWH, low-molecular-weight heparin; INR, international normalized ratio; aPTT, activated partial thromboplastin
time; FFP, fresh frozen plasma; DVT, deep venous thrombosis; CrCl, creatinine clearance; TT, thrombin time. *Risk stratification according to American
College of Chest Physician 2012 guidelines.27
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TABLE 2. Advantages and disadvantages of NOACs compared with
warfarin
Advantages
Freedom from frequent blood monitoring and dose adjustments
Fewer interaction with food and other medications
Fast onset and offset
Rapidly cleared after discontinuation and easier to manage
preoperatively
Reducing thrombosis and fatal bleeding
Disadvantages
Lack of reversal agent
Higher cost per pill
Underdosing when patient forgets to take medication
Dose adjustments required for patients with renal failure
Contraindicated for valve prosthesis, pregnancy, children, and patients
requiring dialysis
Contraindicated for those with neuraxial anesthesia or spinal puncture
Kaneko et al Expert Reviewthoracic, gastrointestinal, neurosurgery) with normal or
mildly impaired renal function (creatinine clearance >
50 mL/min), the last dose should be given 3 days before
surgery, because 48 to 60 hours of interruption will lead
to a minimal anticoagulant effect of<3% to 6% at sur-
gery. The dose adjustments stratified by renal function
are highlighted in Figure 1. For minor surgery, such as
bronchoscopy or pacemaker insertion, a mild to moderate
anticoagulation effect of<12% to 25% has been accepted
at surgery and can be achieved by stopping the NOAC 2
days before the procedure in patients with normal renal
function.
Although these approaches are reasonable according to
the pharmacokinetic profiles, the only supportive empirical
evidence has comes from the RE-LY trial, a randomized
controlled study between dabigatran and warfarin for stroke
prevention in patients with nonvalvular AF, in which a
protocol similar to that shown in Figure 1 was adopted for
patients undergoing a major procedure.9 In that study,
4500 patients had had their anticoagulation interrupted.
No statistically significant difference was found in
perioperative major bleeding among the dabigatran-
treated patients (3.8% with the 110-mg dose, 5.1%
with the 150-mg dose) and warfarin-treated patients
(4.6%).
Monitoring of NOACs
NOACs do not require routine monitoring; however, in
the case of emergency surgery or acute bleeding, blood
monitoring tests can be used.
For dabigatran, the diluted thrombin time can be
determined using the Hemoclot assay (Boehringer
Ingelheim Pharmaceuticals, Ingelheim, Germany). That
assay provides direct assessment of thrombin activity and
can be performed before surgery. A diluted thrombin time
of <65 is ideal before surgery to decrease the risk ofThe Journal of Thoracic and Carbleeding.21 If the diluted thrombin time is not available,
the activated partial thromboplastin time or prothrombin
time can be used to monitor dabigatran to achieve a goal
target similar to that of other anticoagulants (heparin) but
has a lower slope, with an increase in concentration, is
less reliable than the thromboplastin time, and must be
used with caution.22
For factor Xa inhibitors, antifactor Xa assay can be
performed for rivaroxaban and apixaban. The prothrombin
time can also be used, although it is less reliable.23 The
factor Xa assay can estimate the level of factor Xa
inhibitors; however, no data have shown a safe level for
bleeding. The activated partial thromboplastin time has
been unpredictable in factor Xa inhibitors.23
Reversing the Effect of NOACs
Currently, no reversal agent is available for a NOAC,
although a phase II trial is underway for a dabigatran
reversal agent.24 In the case of major bleeding, the NOACs
must first be stopped. The source of bleeding must be
controlled, surgically if needed, and the urine output must
be maintained to continue renal excretion. It is important
to remember that the use of fresh frozen plasma does not
reverse the effect of an NOAC.
If these measures fail, hemodialysis or other renal
replacement therapy can be considered in hemodynami-
cally stable patients taking dabigatran owing to its rela-
tively low plasma protein binding (35%) and high
rate of renal excretion (80%).6 How effective dialysis
would be in the case of factor Xa inhibitors, each of
which has a considerably greater rate of protein binding,
is not known. Activated coagulation factors and prothrom-
bin complex are currently recommended in the reversal of
the NOAC effect. Small reports have been published of
factor VIIa recombinant reversing the activity of dabiga-
tran and rivaroxaban,25 and in vivo studies are ongoing
to confirm the effect of prothrombin complex concentrate.
A reversal agent for factor Xa (Andexanet alfa, PRT4445;
Portola Pharmaceutical, South San Francisco, Calif) and a
synthetic small molecule reversal agent (PER977; Pero-
sphere, Inc, Danbury, Conn) are in late stage
development.
Restarting Anticoagulants Postoperatively
Resuming NOACs after surgery must be done with
caution. The rapid onset of action, with a peak level
occurring 1 to 3 hours after ingestion, can cause signif-
icant bleeding in cases of incomplete hemostasis. Also,
postoperative bowel dysmotility and acid suppression
therapy can affect the absorption of the medication.
Although direct evidence is lacking, resuming NOACs
beyond the second or third day after major cardiotho-
racic surgery, after complete hemostasis and removal
of the chest tube and pacing wires, is recommended.13diovascular Surgery c Volume 148, Number 5 1799
TABLE 3. Adverse events of NOACs in major atrial fibrillation trial (all hazard ratios of stroke and systemic embolism obtained from
noninferiority analysis)
Variable
RE-LY trial ARISTOTLE trial ENGAGE trial ROCKETAF trial
Warfarin
Dabigatran9 (mg bid)
Warfarin
Apixaban12
(5 mg bid) Warfarin
Edoxaban13 (mg bid)
Warfarin
Rivaroxaban14
(20 mg daily)110 150 30 60
Total patients 6022 6015 6076 9081 9120 7036 7034 7035 7133 7131
Stroke and systemic embolism
(%/y)
1.69 1.53 1.11 1.6 1.27 1.5 1.61 1.18 2.4 2.1
HR for stroke and systemic
embolism vs warfarin
0.91* 0.66 0.79 1.07y 0.79y 0.88*
Ischemic stroke (%/y) 1.2 1.32 0.92 1.05 0.97 1.25 1.77 1.25 1.42 1.34
HR for ischemic stroke vs
warfarin
1.11* 0.76 0.92* 1.41 1.00* 0.94*
Hemorrhagic stroke (%/y) 0.38 0.12 0.10 0.47 0.24 0.47 0.16 0.26 0.44 0.26
HR for hemorrhagic
stroke vs warfarin
0.31 0.26 0.51 0.33 0.54 0.59
Major bleeding (%/y) 3.36 2.71 3.11 1.69 0.96 3.43 1.61 2.75 5.42 5.55
HR for major bleeding
vs warfarin
0.80 0.93* 0.57 0.47 0.80 1.04*
Intracranial bleeding (%/y) 0.74 0.23 0.30 0.80 0.33 0.85 0.26 0.39 1.18 0.77
HR for intracranial
bleeding vs warfarin
0.31 0.40 0.42 0.30 0.47 0.67
Major GI bleeding (%/y) 1.02 1.12 1.51 0.86 0.76 1.23 0.82 1.51 2.16 3.15
HR for major GI bleeding
vs warfarin
1.10* 1.50 0.89* 0.67 1.23 P<.001z
RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy; ARISTOLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation;
ENGAGE, ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48); ROCKET AF,
Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; bid, twice
daily; HR, hazard ratio; GI, gastrointestinal. *HR calculation not significantly different. yAnalysis according to 97.5% confidence interval. zHR was not reported in the study’s
report or assigned appendix.
Expert Review Kaneko et alThis recommendation needs to be balanced with the
return of bowel motility in cases of esophageal and
abdominal surgery. In such cases, bridging antico-
agulation with heparin or enoxaparin should be
considered. A summary of the perioperative strategy is
shown in Figure 1. For minor procedures with complete
hemostasis, NOACs can be resumed 6 to 8 hours
postoperatively.19COST OF NOACs
As expected, the cost of NOACs is more expensive
than that of warfarin, which has been on the market
for decades. The annual cost of warfarin is $545
(without INR testing), significantly less than the cost
of dabigatran at $3650, rivaroxaban at $3650, and apix-
aban at $3445.
However, the cost effectiveness has been extensively
studied, especially for stroke prevention in patients
with AF. The elimination of INR testing, decrease in
adverse events, and decrease in the hospital length of
stay will offset the increased drug costs of NOACs. Har-
rington and associates26 created a Markov analysis
model using the data from large randomized controlled
studies of NOACs. They compared the cost between1800 The Journal of Thoracic and Cardiovascular Surwarfarin and NOACs and calculated a willingness to
pay threshold of $50,000 per quality-adjusted life year
gained for each medication. Although warfarin had the
lowest cost ($77,813) followed by rivaroxaban 20 mg
($78,738), dabigatran 150 mg ($82,719), and apixaban
5 mg ($85,326), the quality-adjusted life year gained
was greatest for apixaban (8.47) followed by dabigatran
(8.41), and rivaroxaban (8.26) and lowest for warfarin
(7.97).FUTURE DIRECTIONS
Cardiothoracic surgeons will increasingly encounter
patients taking NOACs. The indications and use of
NOACs are expected to increase as the knowledge and
experience continues to build. Although the RE-ALIGN
trial was stopped owing to the high complication rate,
different regimens for NOACs in the setting of mechan-
ical valves are anticipated. Other conditions that require
anticoagulation, such as heparin-induced thrombocyto-
penia, could be treated in the future using NOACs.
Future approval of a fourth NOAC, namely edoxaban,
might eventually lead to a decrease in their cost and
will be as cost-effective as warfarin. The development
of reversal agents for NOACs will make managementgery c November 2014
Kaneko et al Expert Reviewsafer in urgent situations or in cases in which an over-
dose is suspected.CONCLUSIONS
NOACs offer many advantages over warfarin. They
are more convenient to use than warfarin with fewer drug–
drug and food–drug interactions. Multiple, large,
randomized clinical studies have confirmed the safety and
efficacy of these NOACs. The clinical indications are
increasing, such as venous thromboembolism prevention
and treatment and the prevention of stroke in patients with
nonvalvular AF. Currently, these drugs are not indicated
for anticoagulation for a mechanical prosthesis. Cardiotho-
racic surgeons will face more patients taking these drugs
in the future. Knowledge regarding the pharmacokinetic
profile, interruption and restarting in the setting of surgery,
and treatment in the case of severe bleeding is important
for the treatment of patients taking this medication.
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APPENDIX 1
Definition of Pharmacologic Terms
Bioavailability—the rate and extent to which the active
ingredient or active moiety is absorbed (gastrointes-
tinal) from a drug product and becomes available at
the site of action (Food and Drug Administration
[FDA] definition)
Prodrug—a biologically inactive compound that
does not produce pharmacologic effects until it is
metabolized within the body
T1/2—half-life (the time required for the amount or
concentration of a drug in the body to be reduced to
exactly one-half of a given amount or concentration)
p-gp protein—permeability glycoprotein (cell
membrane transporter, operating as an adenosine
triphosphate-powered drug efflux pump, present in
high concentrations on the apical surface of the
epithelial cell lining of the small intestine and colon
and in other epithelial and endothelial cell linings
p-gp protein inhibitors—amiodarone, azithromycin,
captopril, clarithromycin, cyclosporine, ketoconazole,
quinidine, quinine, ritonavir, verapamil, and tacrolimus
CYP3A4—a member of the cytochrome P450
mixed-function oxidase system, CY3A4 is one
of the most important enzymes involved in the
metabolism of xenobiotics (small foreign organic
molecules) in the human body
CYP3A in vivo inducers (FDA)
Strong inducers: carbamazepine, phenytoin, rifampin,
St John’s wort
Moderate inducers: bosentan, efavirenz, etravirine,
modafinil, nafcillin
Weak inducers: amprenavir, aprepitant, armodafinil,
pioglitazone, prednisone, rufinamide
CYP3A4 inhibitors (FDA)
Rifampin and carbamazepine
CYP3A in vivo inhibitors (FDA)
Strong inhibitors: clarithromycin, conivaptan, grape-
fruit juice (depending on the concentrate), indinavir,
itraconazole, ketoconazole, lopinavir/ritonavir,
nefazodone, nelfinavir, posaconazole, telithromycin,
voriconazole
Moderate inhibitors: ciprofloxacin, diltiazem, eryth-
romycin, fluconazole, fosamprenavir, grapefruit
juice (depending on the concentrate), imatinib, verap-
amil, amprenavir, aprepitant, darunavir/ritonavir
Weak inhibitors: alprazolam, amiodarone, amlodi-
pine, atorvastatin, bicalutamide, cilostazol,
cimetidine, cyclosporine, fluoxetine, fluvoxamine,
isoniazid, nilotinib, oral contraceptives, ranitidine,
ranolazine, ripranavir/ritonavir, zileuton
CYP3A4-specific inhibitors (FDA)
Atazanavir, clarithromycin, indinavir, itraconazole,
ketoconazole, nefazodone, nelfinavir, ritonavir,
saquinavir, telithromycin
CYP3A and p-gp dual inhibitors (FDA)
Cyclosporine A, ketoconazole, nelfinavir, ritonavir,
saquinavir
Strong CYP3A inhibitor and p-gp inhibitors
(FDA): itraconazole, lopinavir/ritonavir, clari-
thromycin, ritonavir, ketoconazole, indinavir/
ritonavir, conivaptan
Medium CYP3A inhibitor and p-gp inhibitors
(FDA): verapamil, erythromycin, diltiazem,
dronedarone
Weak CYP3A inhibitor and p-gp inhibitors:
quinidine, ranolazine, amiodarone, felodipine,
azithromycin
Narrow therapeutic index drugs: drugs that have less
than a twofold difference in the minimum toxic
concentration and minimum effective concentration
in the blood
Wide therapeutic index drugs: drugs that have a greater
than fivefold difference between the minimum toxic
concentration and the minimum effective concentra-
tion in the blood
Quality-adjusted life year: measure of health improve-
ment used by healthcare providers to guide healthcare
resource allocation decisions; better described as
years weighted by their quality; consequently, it takes
into account both the quality and the quantity of life
generated by an intervention
Warfarin Interactions
Drugs
Increasing warfarin’s effect: acetaminophen, aspirin,
allopurinol, amiodarone, cephalosporin, ciproflox-
acin, clopidogrel, diclofenac, fluconazole, metroni-
dazole, omeprazol, tamoxifen
Decreasing warfarin’s effect: azathioprine, antithyroid
drugs, carbamazepine, haloperidol, oral contracep-
tives, phenobarbital, rifampin, vitamin K
Food: cranberry, vitamin K–containing foods (eg,
broccoli, spinach, kale, lettuce, Brussels sprouts,
cabbage)
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